The first iron-catalyzed enantioselective cross-coupling reaction between an organometallic compound and an organic electrophile is reported. Synthetically versatile racemic α-chloro- and α-bromoalkanoates were coupled with aryl Grignard reagents in the presence of catalytic amounts of an iron salt and a chiral bisphosphine ligand, giving the products in high yields with acceptable and synthetically
Intramolecular [2 + 2]cycloadditions of dialkylketenes with alkenes. Regiochemistry of intramolecular [2+2]cycloadditions of ketenes with alkenes
作者:Barry B. Snider、Alban J. Allentoff、Marleen B. Walner
DOI:10.1016/s0040-4020(01)81460-5
日期:——
Unsaturated dialkylketenes 7a, 7b and 7c undergo intramolecular [2 + 2]cycloadditions to give 8a (45%), 9b (23%) and 9c (45%). Intramolecularcycloadditions of dialkylketenes give higher yields than intramolecularcycloadditions of monoalkylketenes, even though dialkylketenes are less reactive than monoalkylketenes. An intramolecular competition experiment with ketene 17 establishes that trans-alkenes
Stereochemically controlled synthesis of unsaturated acids diphenylphosphinoyl (Ph2PO) -ketoacids
作者:Daniel Levin、Stuart Warren
DOI:10.1016/s0040-4039(00)61923-8
日期:1985.1
of cyclic anhydrides or oxidative cleavage of cyclic allyl phosphine oxides gives Ph2PO-ketoacids: reduction, separation of diastereoisomers, and completion of the Horner-Wittigreaction gives singleisomers () or () of unsaturatedacids.
The stereochemically controlled Horner-Wittig route to unsaturated acids: The Baeyer-Villiger rearrangement of α-(1-Ph2PO-alkyl) -cyclohexanones
作者:Daniel Levin、Stuart Warren
DOI:10.1016/s0040-4039(00)84504-9
日期:——
Lithiated alkyl diphenylphosphine oxides attack cyclic epoxides with high stereoselectivity: Baeyer-Villiger rearrangement of the derived ketones gives Horner-Wittig intermediates for the synthesis of unsaturated acids.
AMINE DERIVATIVE HAVING NPY Y5 RECEPTOR ANTAGONIST ACTIVITY
申请人:SHIONOGI & CO., LTD.
公开号:EP2017261A1
公开(公告)日:2009-01-21
This invention provides a compound of the formula (I):
a pharmaceutically acceptable salt or solvate thereof,
wherein
R1 is optionally substituted lower alkyl,
Y is -S(O)n- wherein n is 1 or 2, or -CO-,
R2 is hydrogen or lower alkyl,
R7 is hydrogen or lower alkyl,
X is lower alkylene, lower alkenylene, arylene, cycloalkylene or the like, and
Z is lower alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl or the like.
本发明提供了一种式 (I) 的化合物:
其药学上可接受的盐或溶液、
其中
R1 是任选取代的低级烷基、
Y是-S(O)n- 其中n是1或2,或-CO-、
R2 是氢或低级烷基
R7 是氢或低级烷基
X 是低级烯烃、低级烯烃、芳烃、环烷烃或类似物,以及
Z 是低级烷基、任选取代的碳环烷基、任选取代的杂环烷基或类似物。